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Discussion
DrM. Acker (Philadelphia, Pa). I congratulate you on this feasibil-
ity study and the honest reporting of all of the complications. What I
found most interesting in your talk is actually the slide that com-
pared the compliance of the Paracor device with the CorCap and
pericardium and how unbelievably low it is, and yet still I guess
the theory is that this amount of push-back on diastolic stress is still
enough to have a biological effect. We don’t know what that limit is
because the Paracor almost seems to have no push-back compared
with the other membranes around the heart. I wonder if you would
comment on that.
Dr Klodell. Thank you for that excellent question, Dr Acker.
I think that is exactly true. It is a very interesting concept to think
about. I am sure, as you are aware and I will point out for the audi-
ence, in the early March issue of Circulation the Brigham group
published their results on an ovine model looking at the optimal epi-
cardial pressure that did not result in hemodynamic compromise but194 The Journal of Thoracic and Cardiovascular Surgery c Jandid perhaps promote reverse remodeling, which was approximately
3 mm Hg of epicardial pressure in their study, and that is fairly con-
sistent with what the Paracor device provides. So it may be that this
is about the right amount of epicardial pressure.
Dr M. Anstadt (Dayton, Ohio). I have a question about the im-
plications on diastolic dysfunction. Clearly, the girdling effect of
these passive constraint devices is beneficial for systolic function.
If you examine the basic research around constraint devices, both
passive and active, there are implications that diastolic function
can be impaired, particularly if you look at the right. Now that we
have these clinical studies ongoing, what is being done to assess di-
astolic function after device implantation, particularly in the right
ventricle? You mentioned that you can image these hearts echo-
cardiographically, and with new imaging techniques, ventricular
inhibited [pacemaker], and so forth, we have a critically important
opportunity. Obviously diastolic dysfunction may have contributed
to your reported deaths in these larger hearts. Do you think that con-
straint devices have a negative impact on diastolic function that can
significantly exacerbate the underlying diastolic dysfunction of
heart failure?
Dr Klodell. It is unknown, as you pointed out right now, what
the long-term effects on diastolic dysfunction are going to be. One
of the advantages, again, of this device may be the fact that it is
more compliant and that it triggers whatever neurohormonal signals
there are for the reverse remodeling. Perhaps it will have a beneficial
effect, but I hope the Pivotal Trial is going to answer that question.
I think as far as your comment about the 2 deaths, that is
an interesting thing to consider, although I believe that the 2 deaths
were completely due to patient selection. They were patients who
had a preexisting pulmonary dysfunction, and they did have partic-
ularly large hearts. Trouble began early, they had to be reintubated,
and they spiraled into multisystem organ failure related to their
pulmonary dysfunction.
Dr A. Elami (Jerusalem, Israel). I am referring to a letter to the
editor published 3 months ago in The Journal of Thoracic and Car-
diovascular Surgery regarding a similar device, the CorCap. The
questions raised in this letter were left open, however, and I would
like to raise them again.
I believe everybody in this room is familiar with the echocardio-
graphic appearance of the globally enlarged ventricle in these pa-
tients, especially the bulge of the ventricular septum into the right
side. Your device does not address the septum at all. What is the
mechanism by which you are expecting this device to influence
the septum if it is not addressed by the device? This is the first
question.
The second question is with regard to the systolic interaction
between the device and the heart. We all know that the pressures
in the right side of the heart are much lower than in the left side.
Now during systole, assuming that the tension of the device is
equal and evenly distributed around the heart, why should it pre-
vent the left ventricle from expanding rather than squeeze the
lower pressure right ventricle? What is the mechanism of action
during systole?
Dr Klodell. As far as addressing the septum, you are abso-
lutely correct, none of the restraint devices, meaning the CorCap
or this device, directly address the septum, and again, I think there
is a complex interplay between the potential for systolic augmen-
tation by direct epicardial pressure and neurohormonal remodeling
that goes on. These devices are being used in patients who haveuary 2007
Klodell Jr et al Evolving Technologyongoing clinical deterioration or progressive remodeling without
clinical deterioration. It is unknown how to stop that progress,
but it is known what the consequences are if those patients’ clin-
ical condition continues to progress. It is important to realize the
proposed effect of these devices is thought to involve the complex
interplay of the neurohormonal signals for reverse remodeling, not
direct mechanical effects.
As far as the systolic interaction, again, the epicardial pressure
generated by these devices is very low. Even once the device is
on, you can very easily slip a finger underneath it, and it is compliantThe Journal of Thorenough that it does not have but 3 or 4 mm of direct pressure on the
epicardium. So we have not seen that interplay with the right ventri-
cle to be a problem at this point.
DrM. Acker.We have to move on. As far as that question goes,
this is not a mechanical effect. A mechanical effect is a signal to start
a change in the phenotype at a cellular level, and that gives the neu-
rohormonal changes, and this has been shown well by Tony Sabbah.
So it is not just the girdling effect. That is how the septum gets better.
It is the neurohormonal cascade that is started by this pressure that is
exerted during diastole.acic and Cardiovascular Surgery c Volume 135, Number 1 195
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